bmiMD Review (2026): Prices, Compounded GLP-1s and the Catch

10 Views

SaveSavedRemoved 0

By Goma — BalanzGM Editorial · Published September 13, 2026 · 10 min read · All prices read from each company’s own pages on September 13, 2026

Our verdict — 2.4 / 5

The cheapest compounded GLP-1 we have priced, and the hardest one to price honestly. bmiMD wants $1,188 up front for a year of semaglutide — $99 a month, the lowest figure in our comparison. Whether that is a bargain depends entirely on the dose you end up on, and bmiMD will not tell you your dose before you pay. It is more candid than most rivals about what compounding is, and far less candid about its own numbers. If you want it anyway, take the $129 monthly plan — $30 more a month to avoid prepaying $1,188.

BalanzGM is reader-supported. Some links on this page are affiliate links — if you sign up through them we may earn a commission at no extra cost to you. It does not change a single figure or conclusion below. See our affiliate disclosure.

Not medical advice

This review summarizes what bmiMD publishes about itself, alongside FDA statements, a federal appellate ruling, a court docket and competitors’ published prices — all cited below. It is written by journalists, not clinicians. Whether a GLP-1 is right for you is a decision for a US-licensed clinician who has evaluated you. Full medical disclaimer.

What this review found

The “microdose” costs exactly the same as the full dose — $99 and $139 on the twelve-month tier, matched at all four plan lengths. bmiMD itself calls microdosing “sub-therapeutic.”^[3][4]
No milligram dose is published anywhere. The approved drugs are priced by dose, so without knowing yours you cannot tell whether bmiMD saves you $50 a month or $200.^[6][21]
The twelve-month price is a $1,188 prepayment, and unused months are not refunded if you stop.^[6]
bmiMD’s Trustpilot score is 4.4 from 871 reviews; its BBB rating is F, unaccredited, with 40 complaints in three years.^[12][13]
Novo Nordisk sued bmiMD’s operator in May 2025 over trademarks — a dispute between two companies, not a safety finding. We could not establish how it ended.^[14]

Five terms this page uses

FDA-approved: The FDA reviewed the evidence and approved this exact drug product for this use.
Compounded: Mixed to order by a pharmacy under a prescription. Not FDA-approved, not reviewed for safety, effectiveness or quality. Not a generic.
503A: An ordinary pharmacy that mixes medication one prescription at a time. State-licensed; not routinely FDA-inspected. bmiMD’s Terms say it uses these.^[7]
Titrate: Step your dose up gradually over several months. GLP-1s start low and increase — and the approved drugs get dearer at each step, which is why “the price” is really several prices.
“Essentially a copy”: A pharmacy may only mix its own version of an approved drug when a doctor has documented why one specific patient needs something different. Listing a variant for anyone to buy is not that.^[15]

What bmiMD charges

Every figure below is bmiMD’s “Subscribe & Save” rate: prepaid for the term, then auto-renewing. A one-time, non-renewing purchase costs $30 to $70 more — $159 for a month of semaglutide, $249 for tirzepatide.^[1][2]

Product Compounded	1 month	12 months
Semaglutide	$129	$99
Semaglutide microdose	$129	$99
Tirzepatide	$179	$139
Tirzepatide microdose	$179	$139

Per month, auto-renewing. The 3- and 6-month tiers sit between the columns shown: semaglutide $119 and $109, tirzepatide $159 and $149. Twelve months prepaid comes to $1,188 and $1,668.^[1][2][3][4]

Note the microdose rows: each matches the full-dose row above it to the dollar, at every plan length.

What the approved drugs cost

Compounded GLP-1s took off because the approved drugs listed at $1,000 to $1,350 a month and were unavailable. Neither is true now — and the comparison is no longer one number, because Novo Nordisk and Eli Lilly price by dose while bmiMD does not.

Semaglutide — monthly cash price, September 13, 2026

bmiMD compounded, 12-month prepaid$99

Compounded. $1,188 charged up front. Dose not published.

Wegovy tablets, 1.5 mg starting dose$149

FDA-approved oral semaglutide, approved December 2025. NovoCare cash price.

Wegovy tablets, 25 mg maintenance dose$299

FDA-approved. The 4 mg step is $199.

Tirzepatide — monthly cash price, September 13, 2026

bmiMD compounded, 12-month prepaid$139

Compounded. $1,668 charged up front. Dose not published.

Zepbound vial, 2.5 mg starting dose$299

FDA-approved. Cut from $349 in December 2025.

Zepbound vial, 7.5–15 mg maintenance$449

FDA-approved. The 5 mg step is $399.

Red bars are compounded, green FDA-approved; both charts share a $449 scale. bmiMD’s monthly plans are $129 and $179 (one-time $159 and $249). Every figure is a company’s own published self-pay price.^{[1][2][21][22]}

Read that as a range, not a saving. Against the starting dose of an approved semaglutide pill, bmiMD is $50 a month cheaper; against the 25 mg maintenance dose the approved label steps up to, $200 cheaper. Because bmiMD publishes no dose, you cannot know which comparison you are making. A second approved pill, Eli Lilly’s Foundayo (orforglipron, approved April 2026), also starts at $149, rising to $299.^[21][23]

What “compounded” means now

The FDA declared the tirzepatide shortage resolved in October 2024, reaffirming it that December, and the semaglutide shortage in February 2025 — ending the legal basis for compounding copies at scale.^[15] The industry sued, lost, appealed and lost again: the Fifth Circuit affirmed for the FDA on August 27, 2026.^[19] On April 30, 2026 the FDA proposed striking semaglutide, tirzepatide and liraglutide from the list of substances large compounding plants may work from, finding “no clinical need” to do so.^[20]

The FDA, in its own words: “Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”^[16] bmiMD carries a version of this on its product pages — more than several competitors do. It pairs it with “produced in FDA-registered facilities.” Registration is not approval.^[1][2]

The market has already moved: under a March 2026 agreement in which Novo Nordisk voluntarily dismissed its suit, Hims & Hers stopped advertising compounded GLP-1s, and Ro now sells brand-name only.^[24][25] bmiMD has not followed.

The question a twelve-month prepayment raises. If enforcement reaches bmiMD’s products partway through a year you have paid for, what happens to the balance? Nothing bmiMD publishes says: its refund policy covers cancellation by the customer, not interruption by a regulator, and we found no clause addressing it.^[5][7] A monthly plan does not carry that exposure.

The microdose puzzle

bmiMD sells “GLP-1 Microdose” and “GLP-1/GIP Microdose” as separate products, in its own words using “lower, sub-therapeutic doses… to provide gentle metabolic and wellness support without primarily targeting weight loss.”^[4]

A sub-therapeutic dose at the therapeutic price. Semaglutide Microdose is $99/$109/$119/$129 across the four plan lengths; Compounded Semaglutide is $99/$109/$119/$129. The tirzepatide pair match at $139/$149/$159/$179. Four tiers, two products, eight identical prices.^[1][2][3][4] With no milligram figure published for either, a buyer cannot see what the difference is — only that it is not the price.

“Microdosing” is not a term in FDA compounding guidance, and we found no published trials supporting sub-therapeutic dosing for the “metabolic and wellness support” bmiMD describes. It is legally fragile too: the “essentially a copy” rule is satisfied by a doctor documenting one patient’s need, not by a company listing a lower dose for sale.^[15][17]

What you are agreeing to

The $99 price is a $1,188 prepayment, and the help center is explicit about stopping early: cancelling “does not entitle you to reimbursement for remaining months once treatment fulfillment has begun.”^[6] A $50 non-refundable intake fee applies once your intake form is submitted, disclosed on the refunds page and not on any product page.^[5] You cancel by email only — at a company the BBB rates F for failing to respond to complaints, so send it early and keep the sent copy. The Terms set the deadline at 48 hours before your processing date; the help center recommends 48 business hours, which is longer. Allow the longer one.^[6][7]

What you cannot find anywhere is a dose. Across every product page and the help center there is no milligram figure and no titration schedule; your “full treatment plan, dosage, and instructions are inside your bmiMD patient portal,” visible after you enrol and your intake is reviewed.^[6] The plan covers medication, provider review, supplies where applicable and shipping — you inject it yourself from a vial.^[6] That matters more for a compounded multi-dose vial than a pre-measured pen — the FDA’s 2024 alert described patients drawing five to twenty times their intended dose from this kind of product, some requiring hospitalization.^[18]

The company behind bmiMD

bmiMD is operated by Medccm Inc. of 420 Lexington Avenue, New York. Its Terms say it sources from “licensed 503a compounding pharmacies” and name one — Precision Compounding Pharmacy, Bellmore, New York — while adding that customers may select an alternate, so it is not established as the sole fulfiller. The federal NPI registry lists an active compounding pharmacy at that address, registered as Precision Medication Inc. — the same address, so presumably the same business under a trading name, though bmiMD does not state the relationship.^[7][26] Naming a pharmacy at all is more than most competitors do; no licence number or accreditation is published.

The public record is uneven. bmiMD’s Trustpilot score is 4.4 from 871 reviews, 13% one-star — roughly 113 people.^[12] The Better Business Bureau rates it F, does not accredit it, and cites failure to respond to complaints. Of the 40 complaints in three years, the recurring themes are billing and shipping: one describes being “charged $507 without notice, prompt, or authorization,” another being charged twice in separate months, another medication “in transit 4 days WITHOUT BEING KEPT ON ICE.”^[13] The two are not in conflict: Trustpilot collects reviews from customers a company invites, while a BBB grade reflects unanswered complaints rather than product quality. If you are wary of subscriptions, read the complaints before prepaying a year.

Its marketing runs ahead of that record. The homepage claims “80,000+ members” and carries testimonials — “17lbs in 21 days,” “22 pounds in seven weeks” — as self-hosted text with no verification or typicality disclaimer.^[9] bmiMD’s listing on the affiliate network Katalys goes further, advertising “a 4.9-star average rating” and members “reporting an average of 15% body fat loss.”^[11] The 4.9 is contradicted by bmiMD’s own Trustpilot page; nothing published supports the 15%, and GLP-1 trials measure body weight, not body fat. We could not establish who wrote that listing copy.

One further matter of public record: on May 21, 2025 Novo Nordisk A/S sued Medccm, Inc. d/b/a bmiMD for trademark infringement in the Eastern District of New York, case 2:25-cv-02846. The last public docket entry, dated November 4, 2025, referred the case to a settlement conference set for December 15, 2025. No disposition has appeared on the public docket since, and the case is not marked terminated. We could not establish how or whether it resolved; a complaint is an allegation, not a finding.^[14]

What we could not verify

Any milligram dose or titration schedule, for any product including the microdose line.
Who evaluates you. Product pages promise “a same-day telehealth consultation with a board-certified Medical Provider”; the help center says everything runs through the portal “with no appointments needed.”^[1][6]
Whether bloodwork is required. Product pages mention “metabolic testing as necessary,” but no test, panel or requirement is described.^[1]
Any named physician, medical director or advisory board. The only officer we could name is a chief marketing officer.
The outcome of Novo Nordisk v. Medccm. The public docket stops at November 4, 2025.
Availability in your state. Every GLP-1 page says “all 50 states,” but other bmiMD products are narrower — metformin 49, its vitamin injection 48 — and the Terms reserve service to states “in which we offer the Service.”^[7][10]

Check bmiMD’s current pricing yourself

Prices here move fast. The figures above are what we read on September 13, 2026; only bmiMD’s own page is authoritative for today’s price, plan terms and state availability.

Affiliate link. We may earn a commission at no cost to you.

See bmiMD’s semaglutide pricing Compounded vs brand-name

How we rated bmiMD

Editorial rating — based on our analysis

2.4 / 5

Six criteria, equally weighted, scored against our published telehealth rubric. The rubric scores what a service discloses, not what happened to its customers — bmiMD’s F rating and complaint record sit outside it and should be read separately, above.

1. What is actually prescribed3.2

Says plainly that its GLP-1s are compounded and not FDA-approved, and its Terms identify a 503A pharmacy.^[1][7] Loses ground for the “FDA-registered facilities” softener and for publishing no dose.

2. Who evaluates you, and where2.2

Its own two descriptions of the intake contradict each other, no clinician or medical director is named, and “metabolic testing as necessary” is the only reference to lab work.^[1][6]

3. Safety information published2.5

A real safety page carries the boxed warning and MedWatch reporting, though the warnings reproduced are the branded drugs’.^[8] The FDA’s 2024 vial dosing-error alert is unaddressed; homepage testimonials carry no typicality disclaimer.^[9]

4. The terms you are agreeing to2.0

All published, which counts. But prepaid months are forfeited on exit, the $50 intake fee appears only on the refunds page, and nothing addresses a regulatory interruption mid-year.^[5][6]

5. Whether the claims are supportable1.8

A “4.9-star average” advertised on bmiMD’s affiliate-network listing is contradicted by its own Trustpilot page, “15% body fat loss” has no published basis, and the homepage testimonials run ahead of labelled trial results.^[11][12]

6. What the service does not say2.7

Credit for naming a pharmacy and a 503A designation — few rivals do. Against that: no doses, no licence numbers, and an intake process described two incompatible ways.

Scored against the telehealth rubric on our methodology page: (3.2 + 2.2 + 2.5 + 2.0 + 1.8 + 2.7) ÷ 6 = 2.4.

Reasonable fit if

You have already decided on a compounded GLP-1 and want the lowest price we have found.
You are confident you will stay on treatment for the full twelve months you prepay.
You already have a prescription for a specific dose and can confirm bmiMD will supply it. Approved products get dearer as you titrate up and bmiMD’s price does not move — though it also does not move for the dose it calls “sub-therapeutic,” so a flat price is not by itself evidence of value.
You value that a pharmacy and a 503A designation are named at all.

Look elsewhere if

You want the FDA-approved drug. Wegovy tablets and Foundayo both start at $149, with no commitment and a known dose.
You are unsure you will tolerate a GLP-1. Prepaid months are forfeited and a $50 fee applies once intake is submitted.
You need to know your dose, or your dose-by-dose price, before you pay.
You want a named clinician, or a clear answer on whether bloodwork happens.
An F rating from the BBB and 40 complaints would give you pause before prepaying a year.

Frequently asked questions

Is bmiMD’s semaglutide the same as Wegovy or Ozempic?

No. bmiMD sells a compounded preparation — mixed to order and not FDA-approved, so the agency has not reviewed it for safety, effectiveness or quality.^[16] Nor is it a generic: generics must prove equivalence through an FDA pathway. Compounded versions do not.

What happens if I cancel a 12-month bmiMD plan early?

You forfeit the unused months — bmiMD’s help center says cancelling “does not entitle you to reimbursement for remaining months once treatment fulfillment has begun” — and a separate $50 non-refundable fee applies once your intake form has been submitted.^[5][6]

Is bmiMD actually cheaper than the FDA-approved drug?

It depends on your dose, which bmiMD does not publish. Its semaglutide is $99 a month prepaid for a year, against $149 for Wegovy tablets at the 1.5 mg starting dose and $299 at the 25 mg maintenance dose — a gap of $50 or $200 depending where you land.^[21] Month to month it is $129 against $149. For tirzepatide the gap is wider, since no approved oral tirzepatide exists and the Zepbound vial runs $299 to $449.^[22]

Who qualifies for a GLP-1, and what are the side effects?

Prescribing generally starts at a BMI of 30, or 27 with a weight-related condition. The approved products carry a boxed warning for thyroid C-cell tumours and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2; common side effects are gastrointestinal.^[8][17] That is a conversation for a clinician, not a questionnaire — our guide to who qualifies goes into it properly.

Bottom line

bmiMD sells a self-described sub-therapeutic dose at the full-dose price, advertises a star rating its own Trustpilot page contradicts, holds an F from the Better Business Bureau, and will not tell you the dose you are buying until you have committed to a year of it.

Set against that: it says plainly that its GLP-1s are compounded and not FDA-approved, names a pharmacy and a 503A designation, and its $99 is the lowest number on our board.

But you cannot know that in advance, because the figure that would settle it is the one bmiMD withholds. Price the approved options first — at the starting dose they are $50 a month away, with a known dose and no commitment. If you have weighed that and still want compounded, take the monthly plan rather than the year: $30 a month is a fair price for not prepaying $1,188 into a category whose legal ground has been giving way all year.